The BDO Midlands Transaction Services Team has provided Financial and Taxation Due Diligence services in connection with the sale of Cobra Biologics Holding AB ("Cobra") to Cognate BioServices, Inc. ("Cognate")
Cobra, with facilities in both the UK and Sweden, is a leading international contract development and manufacturing organisation (CDMO) providing plasmid and viral vector for pre-clinical, clinical and commercial supply. Cognate headquartered in Memphis, Tennessee, USA is a leading CDMO specialised in cell and cell-mediated gene therapy products.
The transaction establishes a global, industry leading enhanced services provider in manufacturing solutions and drug development to the cell and gene immunotherapy and regenerative industries. The combined entities will leverage industry knowledge generated over a number of years and provide and increase global capability and provide an integrated and scalable solutions to meet ever changing client needs.
The BDO team were a pleasure to work with. They met challenging, short deadlines and ensured that the process went as smooth as possible. The team produced an excellent, concise due diligence report.
Lee Warren, Finance Director, Cobra Biologics